These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11750101)

  • 1. A schedule of recombinant Mpl ligand highly effective at preventing lethal myelosuppression in mice given carboplatin and radiation.
    Abushullaih BA; Pestina TI; Srivastava DK; Jackson CW; Daw NC
    Exp Hematol; 2001 Dec; 29(12):1425-31. PubMed ID: 11750101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mpl ligand prevents lethal myelosuppression by inhibiting p53-dependent apoptosis.
    Pestina TI; Cleveland JL; Yang C; Zambetti GP; Jackson CW
    Blood; 2001 Oct; 98(7):2084-90. PubMed ID: 11567994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single intravenous dose of murine megakaryocyte growth and development factor potently stimulates platelet production, challenging the necessity for daily administration.
    Daw NC; Arnold JT; Abushullaih BA; Stenberg PE; White MM; Jayawardene D; Srivastava DK; Jackson CW
    Blood; 1998 Jan; 91(2):466-74. PubMed ID: 9427699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential role of Stat5 isoforms in effecting hematopoietic recovery induced by Mpl-ligand in lethally myelosuppressed mice.
    Pestina TI; Jackson CW
    Exp Hematol; 2003 Dec; 31(12):1198-205. PubMed ID: 14662325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multilineage hematopoietic recovery by a single injection of pegylated recombinant human megakaryocyte growth and development factor in myelosuppressed mice.
    Shibuya K; Akahori H; Takahashi K; Tahara E; Kato T; Miyazaki H
    Blood; 1998 Jan; 91(1):37-45. PubMed ID: 9414267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor.
    Harker LA; Marzec UM; Kelly AB; Cheung E; Tomer A; Nichol JL; Hanson SR; Stead RB
    Blood; 1997 Jan; 89(1):155-65. PubMed ID: 8978288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelets exposed to elevated levels of endogenous thrombopoietin in vivo have a reduced response to megakaryocyte growth and development factor in vitro.
    Nishiyama U; Morita H; Torii Y; Kuwaki T; Shimizu E; Akahori H; Kato T; Miyazaki H
    Thromb Haemost; 2001 Jan; 85(1):152-9. PubMed ID: 11204567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of c-mpl ligands after total body irradiation (TBI) with and without allogeneic hematopoietic stem cell transplantation: low-dose TBI does not prevent sensitization.
    Nash RA; Takatu A; Feng Z; Slichter S; Abrams K; Espino G; Gass MJ; Georges GE; McSweeney PA; Shulman HM; Storb R
    Biol Blood Marrow Transplant; 2002; 8(7):360-7. PubMed ID: 12171482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human ligand for MPL, megakaryocyte growth and development factor (MGDF), stimulates thrombopoiesis in vivo in normal and myelosuppressed baboons.
    Andrews RG; Winkler A; Myerson D; Briddell RA; Knitter GH; McNiece IK; Hunt P
    Stem Cells; 1996 Nov; 14(6):661-77. PubMed ID: 8948024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice.
    Akahori H; Shibuya K; Ozai M; Ida M; Kabaya K; Kato T; Miyazaki H
    Stem Cells; 1996 Nov; 14(6):678-89. PubMed ID: 8948025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prolonged hematologic effects of a single injection of PEG-rHuMGDF in normal and thrombocytopenic mice.
    Ulich TR; del Castillo J; Senaldi G; Cheung E; Roskos L; Young J; Molineux G; Guo J; Schoemperlen J; Munyakazi L; Murphy-Filkins R; Tarpley JE; Toombs CF; Kaufman S; Yin S; Nelson AG; Nichol JL; Sheridan WP
    Exp Hematol; 1999 Jan; 27(1):117-30. PubMed ID: 9923450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Thrombocytopoietic Efficacy of Pegylated Recombinant Human Interleukin-11 Mutein in Myelosuppressed Mice].
    Ma SS; Ho SH; Wang HL; Nie LY; Xu SS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1511-1517. PubMed ID: 27784384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Further examination of various administration protocols of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia in myelosuppressed mice.
    Akahori H; Ozai M; Ida M; Shibuya K; Kato T; Miyazaki H
    Ther Apher; 1998 Feb; 2(1):58-64. PubMed ID: 10227790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice.
    Kabaya K; Akahori H; Shibuya K; Nitta Y; Ida M; Kusaka M; Kato T; Miyazaki H
    Stem Cells; 1996 Nov; 14(6):651-60. PubMed ID: 8948023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor in mice.
    Kabaya K; Shibuya K; Torii Y; Nitta Y; Ida M; Akahori H; Kato T; Kusaka M; Miyazaki H
    Bone Marrow Transplant; 1996 Dec; 18(6):1035-41. PubMed ID: 8971370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic effects of pegylated recombinant human megakaryocyte growth and development factor in combination with recombinant murine granulocyte colony-stimulating factor in a murine model of myelosuppression.
    Coleman D; Fairchild D; Schindler-Horvat J; Munyakazi L; Neumann TA
    Toxicol Sci; 1998 Sep; 45(1):77-87. PubMed ID: 9848114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer.
    Basser RL; Underhill C; Davis I; Green MD; Cebon J; Zalcberg J; MacMillan J; Cohen B; Marty J; Fox RM; Begley CG
    J Clin Oncol; 2000 Aug; 18(15):2852-61. PubMed ID: 10920133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Megakaryocyte growth and development factor stimulates enhanced platelet recovery in mice after bone marrow transplantation.
    Molineux G; Hartley CA; McElroy P; McCrea C; McNiece IK
    Blood; 1996 Aug; 88(4):1509-14. PubMed ID: 8695873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation.
    Schuster MW; Beveridge R; Frei-Lahr D; Abboud CN; Cruickshank S; Macri M; Menchaca D; Holden J; Waller EK
    Exp Hematol; 2002 Sep; 30(9):1044-50. PubMed ID: 12225796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single dose of thrombopoietin shortly after myelosuppressive total body irradiation prevents pancytopenia in mice by promoting short-term multilineage spleen-repopulating cells at the transient expense of bone marrow-repopulating cells.
    Neelis KJ; Visser TP; Dimjati W; Thomas GR; Fielder PJ; Bloedow D; Eaton DL; Wagemaker G
    Blood; 1998 Sep; 92(5):1586-97. PubMed ID: 9716586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.